Health Condition 1: K802- Calculus of gallbladder without cholecystitis Health Condition 2: null- Patients undergoing Laparoscopic Cholecystectomy
Conditions
Interventions
Intervention1: Desflurane: Inhaled Anaesthetic Agent
PHYSICAL PROPERTIES
Chemical name â?? 1,2,2,2-tetrafluoroethyl difluoromethyl Ether
Molecular weight[g] â?? 168
Boiling Point [o C] - 24
Vapour pre
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: 1) ASA I and II patients. 2) Age group 20â??60 years. 3) Patients undergoing Laparoscopic Cholecystectomy
Exclusion criteria
Exclusion criteria: 1) Moderate to severe underlying Cardiopulmonary dysfunction. 2) Moderate to severe underlying Hepatic dysfunction. 3) Moderate to severe underlying Renal dysfunction. 4) Moderate to severe underlying Endocrine dysfunction. 5) Moderate to severe underlying Neurological dysfunction. 6) Pregnancy. 7) Psychiatric disorder. 8) History of drug allergy or abuse. 9) Documented allergic reaction to the anaesthetic agent being used. 10) Patients taking CNS depressants. 11) Patient refusal to participate in the study. 12) Intra operative conversion of procedure from laparoscopic to open.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) To compare the time taken for awakening the patient after inhalational agent is switched off. 2) To compare the time taken for verbal response to occur after the inhalational agent is switched off. 3) To compare the time taken for complete recovery of patient as measured by a modified Aldrete score of â?¥ 9Timepoint: 1) At the time of administering Reversal 2) At the time of Extubation 3) 1 minute after extubation 4) 3 minutes after extubation 5) 5 minutes after extubation 6) 10 minutes after extubation 7) 15 minutes after extubation 8) 30 minutes after extubation 9) Time of switching off inhalational agent( to co incide with skin closure by the surgeon) 10) Time of first eye opening after switching off the agent 11) Time of first verbal response after switching off the agent | — |
Secondary
| Measure | Time frame |
|---|---|
| To document adverse effects, if any, during extubation or early recovery such as excessive secretions, coughing or laryngospasm.Timepoint: From switching off the inhalational agent, to complete awakening | — |
Countries
India
Contacts
Public ContactDr Gauri Raman Gangakhedkar
P.D. Hinduja National Hospital and Medical Research Centre
Outcome results
None listed